Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2003

View Archived Issues

ETB receptors and GIRKs: novel targets for the treatment of pain

New GSK-3 inhibitors with potential in diabetes, etc.

Gruenenthal patent covers new compounds for pain, depression, etc.

Shionogi researchers describe a novel series of HIV integrase inhibitors

New ADAM-10 inhibitors and their use in cancer and arthritis described by Exelixis

Novel NK1 antagonists for urinary incontinence and other uses in Kyorin pipeline

Noncalcemic vitamin D analogue designed by Wisconsin researchers

New anthelminthic agents patented by Kitasato Institute scientists

BMS-387032: a potent and selective CDK2 inhibitor undergoing clinical evaluation

Decolonization of the GI tract with ramoplanin: a novel option for management of VRE infection

Preclinical pharmacological activity of the novel aromatase inhibitor MEN-11066

Chiron presents antiangiogenic and antiproliferative agent targeting growth factor tyrosine kinases

Ariad compound for bone cancer/metastases a highlight of the AACR meeting

H3 Pharma acquires rights to vapreotide from Debiopharm

Patient dosing begins in Targeted Genetics' largest CF trial to date

Improved efficacy for niacin/lovastatin on lipid profile in hyperlipidemia

Santarus completes phase III patient enrollment in upper GI bleeding prevention trial

IX-1003 completes phase I testing

HCV-371 has no impact on HCV RNA levels in phase Ib study

Effective inhibition of thrombosis and moderate hemorrhage risk with melagatran in baboons

Pivotal European study of Adhibit commences enrollment

Better survival and response rate found with letrozole vs. tamoxifen in advanced breast cancer

Relationship between breast cancer risk and isoflavone consumption in Japanese women

Kosan achieves KOS-862 production goal

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.